Beladakere Ramaswamy SMD, Singh S, Hooshmand S, et al. Current and upcoming treatment modalities in myasthenia gravis. J Clin Neuromuscul Dis. 2021;23(2):75–99.

Article  PubMed  Google Scholar 

Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dresser L, Wlodarski R, Rezania K, et al. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021;20(1):1–6.

Article  Google Scholar 

Alhaidar MK, Abumurad S, Soliven B, et al. Current treatment of myasthenia gravis. J Clin Med. 2022;11(6):1–23.

Article  Google Scholar 

Habib AA, Ahmadi Jazi G, Mozaffar T. Update on immune-mediated therapies for myasthenia gravis. Muscle Nerve. 2020;62(5):579–92.

Article  CAS  PubMed  Google Scholar 

Vanoli F, Mantegazza R. Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics. 2022;19(3):1–14.

Article  Google Scholar 

Argenx. Vyvgart (efgartigimod alfa-fcab) injection, for intravenous use: US prescribing information; 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8aefc8e3-26d6-4ff6-aab9-a7542927e084. Accessed 7 Feb 2023.

European Medicine Agency. Vyvgart (efgartigimod alfa): EU summary of product characteristics; 2022. https://www.ema.europa.eu/en/documents/product-information/vyvgart-epar-product-information_en.pdf. Accessed 7 Feb 2023.

Pharmaceuticals and Medical Devices Agency. Vyvgart® for intravenous infusion 400 mg: Japanese prescribing information; 2022. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/6399430. Accessed 11 Jan 2023.

Huijbers MG, Plomp JJ, van Es IE, et al. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Exp Neurol. 2019;317:133–43.

Article  CAS  PubMed  Google Scholar 

Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Investig. 2018;128(10):4372–86.

Article  PubMed  PubMed Central  Google Scholar 

Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–36.

Article  CAS  PubMed  Google Scholar 

Howard JF Jr, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pulley M, Pasnoor M, Gelinas D, et al. The effect of obesity in efficacy and safety in the ADAPT trial of efgartigimod for generalized myasthenia gravis [abstract no. 194]. In: The American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting. 2022.

Bril V, Murai H, Vu T, et al. Analysis of efgartigimod efficacy across patient populations and myasthenia gravis specific scales: results of the phase 3 ADAPT study [abstract no. 304]. Ann Neurol. 2021;90(Suppl 27):S28.

Google Scholar 

Karam C, Vu T, Bril V, et al. Efgartigimod treatment of patients with generalized myasthenia gravis demonstrates consistent improvements across all muscle subgroups and regardless of background immunosuppressive therapy [abstract]. Muscle Nerve. 2021;64(Suppl 1):S90–1.

Google Scholar 

Howard J, Bril V, Vu T, et al. Examination of the efficacy, safety, and tolerability of efgartigimod in acetylcholine receptor autoantibody seronegative patients with generalized myasthenia gravis: subgroup analysis of phase 3 [abstract no. 6]. Muscle Nerve. 2021;64(Suppl 1):S5.

Google Scholar 

Jacob S, Howard J, Bril V, et al. Long-term assessment of efgartigimod in patients with generalised myasthenia gravis: ADAPT+ study interim results [abstract]. J Neurol Neurosurg Psychiatry. 2022;93(9): e2.

Article  Google Scholar 

Howard J, Bril V, Vu T, et al. Long-term safety, tolerability and efficacy of efgartigimod in patients with generalized myasthenia gravis: interim results of the ADAPT+ study [abstract no. 108]. In: The American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting. 2022.

European Medicine Agency. Vyvgart: EU assessment report; 2022. https://www.ema.europa.eu/en/documents/assessment-report/vyvgart-epar-public-assessment-report_en.pdf. Accessed 7 Feb 2023.

Muppidi S, Pasnoor M, Gelinas D, et al. Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: integrated interim analysis of infection risk and hematological changes [abstract no. 193]. In: The American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting. 2022.

Guptill J, Sleasman J, Steeland S, et al. Effect of efgartigimod, a neonatal Fc receptor blocker, on humoral vaccine responses in autoimmune patients [abstract]. Muscle Nerve. 2021;64(Suppl 1):S91.

Google Scholar 

Qi C, Hughes T, Wang J, et al. Risk benefit analysis of treatment for patients with myasthenia gravis [abstract no. 27]. In: The American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting. 2022.

Chen R, Zhang N, Gao L, et al. Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis. Expert Opin Investig Drugs. 2021;30(12):1231–40.

Article  CAS  PubMed  Google Scholar 

Song Z, Zhang J, Meng J, et al. Different monoclonal antibodies in myasthenia gravis: a bayesian network meta-analysis. Front Pharmacol. 2021;12(790834):1–10.

CAS  Google Scholar 

Lien P-W, Agboola F, Joshi M, et al. Cost-effectiveness of eculizumab and efgartigimod for the treatment of generalized myasthenia gravis [abstract no. P1–1 virtual]. Neurology. 2022;98(18 Suppl):1531.

Google Scholar